Episode Details
Back to Episodes
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
Published 1 year, 8 months ago
Description
Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.